The global peptide therapeutics market value was USD 36.1 billion in 2023, driven by the rising advancements in peptide synthesis technologies across the globe. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 to achieve a value of USD 69.9 billion by 2032.
The oral segment based on the route of administration is expected to account for a significant share in the market. The growing efforts by the drug developers to facilitate oral delivery of peptides due to the increased inclination of people towards minimally invasive treatments are likely to boost the segment growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Additionally, orally delivered peptide therapeutics facilitate patient compliance, diversify the treatment options, offer ease of administration, and boost marketability. These factors are likely to aid the market growth. Moreover, the expansion of the major biotechnology companies specialising in the oral delivery of peptides is anticipated to bolster the market growth in the forecast period.
The peptide therapeutics industry in North America is driven by factors such as the strong pharmaceutical and biopharmaceutical ecosystem in the region, easy access to medical facilities, and rapid growth in the development of therapeutic proteins. A considerable increase in the number of protein-based drugs, coupled with the increased investments to develop new therapeutic proteins for a wide range of ailments has supported the regional market expansion. In addition, the favourable government policies encouraging the sales of peptide-based drugs are anticipated to further aid the market growth in the region.
Peptide therapeutics can be defined as peptide-based therapeutics used to treat various diseases. Peptide therapeutics mimic the functions of the naturally occurring peptides in the human body, further serving as a promising basis for targeting a range of diseases. They are often well tolerated by the body and have the potential for decreased off-target side effects.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on marketing type, the market has been segmented into:
The segmentation of the market based on application is as follows:
On the basis of route of administration, the market is divided into:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The rising cases of chronic diseases and the increasing prevalence of cancer are driving the global peptide therapeutics industry. Additionally, there has been a significant surge in the incidences of metabolic diseases such as diabetes among the geriatric population. Unhealthy and poor lifestyles led by people with hectic and busy schedules are likely to increase the risk of various kinds of diseases, thereby enhancing the therapeutic use of peptide drugs for different treatments. Hence, these factors are likely to provide impetus to the peptide therapeutics industry. The complexity associated with large peptides is likely to restrain the market growth, however, the growing availability of biosimilars is expected to aid the market in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report gives a detailed analysis of the following key players in the global peptide therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
|Scope of the Report
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Applications
|Breakup by Route of Administration
|Breakup by Type of Manufactures
|Breakup by Distribution Channels
|Breakup by Region
|Report Price and Purchase Option
|Explore our purchase options that are best suited to your resources and industry needs.
|Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Peptide Therapeutics Market Overview
3.1 Global Peptide Therapeutics Market Historical Value (2017-2023)
3.2 Global Peptide Therapeutics Market Forecast Value (2024-2032)
4 Global Peptide Therapeutics Market Landscape
4.1 Global Peptide Therapeutics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Peptide Therapeutics Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Distribution Channel
4.2.3 Analysis by Applications
5 Global Peptide Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Peptide Therapeutics Market Segmentation
6.1 Global Peptide Therapeutics Market by Type
6.1.1 Market Overview
6.1.2 Branded Peptide
6.1.3 Generics Peptide
6.2 Global Peptide Therapeutics Market by Applications
6.2.1 Market Overview
6.2.2 Cancer, Cardiovascular Disease
6.2.3 Metabolic Disease
6.2.4 Respiratory Disease
6.2.5 Infectious Disease
6.3 Global Peptide Therapeutics Market by Route of Administration
6.3.1 Market Overview
6.4 Global Peptide Therapeutics Market by Type of Manufactures
6.4.1 Market Overview
6.4.2 In House
6.5 Global Peptide Therapeutics Market by Distribution Channels
6.5.1 Market Overview
6.5.2 Hospitals Pharmacies
6.5.3 Retail Pharmacies
6.5.4 Online Pharmacies
6.6 Global Peptide Therapeutics Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Peptide Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Peptide Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Peptide Therapeutics Market
9.1 Market Share by Country
10 Latin America Peptide Therapeutics Market
10.1 Market Share by Country
11 Middle East and Africa Peptide Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Supplier Landscape
18.1 F. Hoffmann-La Roche Ltd.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.2 GlaxoSmithKline plc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.3 Novartis AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.4 Pfizer, Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.6 Takeda Pharmaceutical Company Limited
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.7 Teva Pharmaceutical Industries Ltd
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.8 Ipsen Pharma
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.11 Merck Sharp & Dohme Corp.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.12 Novo Nordisk A/S
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.13 PolyPeptide Group
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.14 CordenPharma International
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
19 Global Peptide Therapeutics Distribution Model (Additional Insight)
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The peptide therapeutics were valued at USD 36.1 billion in 2023.
The market is expected to grow at a CAGR of 7.6% from 2024 to 2032 to reach a value of USD 69.9 billion by 2032.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drivers of the industry, such as the rising cases of chronic diseases such as cancer and tuberculosis, advancements in the field of medical science, and the growing healthcare spending, are expected to fuel the market growth.
The key market trends guiding the growth of the industry include the growing investments by the leading life sciences companies in research and development activities.
Generic and branded are the major marketing types considered within the market report.
Gastrointestinal disorders, neurological disorders, metabolic disorders, cancer, and cardiovascular, among others are the different applications of peptide therapeutics.
Parenteral, and oral, among others are the different routes of administration utilised in the industry.
The major players in the industry are Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, and Amgen Inc., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.